TCR2 Therapeutics (TCRR) PT Lowered to $38 at BMO Capital, Following Strategic Business Update
- Wall Street ends first day of third quarter with solid rebound
- Tesla (TSLA) Delivered 254,695 EV Units in Q2, Below Consensus
- Goldman Sachs Warns Clients of More Equity Market Losses in Second Half of 2022
- Kohl's (KSS) Falls 15% After Ending Sale Talks With Franchise Group and Issuing Q2 Warning
- General Motors Warns It Has 95k Vehicles in Inventory Without Certain Components
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
BMO Capital analyst Matthew Luchini lowered the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $38.00 (from $44.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anglo American Plc. (AAL:LN) (NGLOY) PT Raised to GBP38 at JPMorgan
- Ultra Tech Cement Ltd (UTCEM:IN) PT Lowered to INR5,850 at JPMorgan
- Boliden AB (BOL:SS) (BDNNF) PT Lowered to SEK340 at JPMorgan
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!